Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China.

Sini LiLiubao PengChongqing TanXiaohui ZengXiaomin WanXia LuoLidan YiJianhe Li

Published in: PloS one (2020)

For patients with advanced gastric or gastro-oesophageal junction adenocarcinoma who fail first-line chemotherapy, our results are conducive to the multilateral drug price guidance negotiations of RAM in China.

Keyphrases

locally advanced
papillary thyroid
squamous cell carcinoma
emergency department
squamous cell
young adults
adverse drug
drug induced